

Case-Control Study on Tracking Nursing Home Patients with Dementia

<https://neurodegenerationresearch.eu/survey/case-control-study-on-tracking-nursing-home-patients-with-dementia/>

Title of study

Case-Control Study on Tracking Nursing Home Patients with Dementia

Acronym for cohort

IDEM

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Yves

Name of Principal Investigator - Last name

Rolland

Address of institution -Institution

CHU Toulouse

Address of institution - Street address

Hôpital La-Grave-Casselardit 170 Avenue de Casselardit

Address of institution - City

Toulouse

Address of institution - Postcode

31059

Country

France

Website

Contact email

rolland.y@chu-toulouse.fr

Funding source

PHRC 2009

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias|Neurodegenerative disease in general

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

To assess the prevalence of systematically tracking dementia cases in EHPADs (institutions for dependent elderly people) within multidisciplinary team meetings.

Q2b. What distinguishes this case-control study from other studies?

It is performed in nursing home with a large number of residents included. The organization of multidisciplinary team meetings for dementia between patients' physicians, coordinator doctor and experts of memory clinics

Q3a. i) Number of publications that involve use of your cohort to date

1

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

J Nutr Health Aging. 2013 Feb;17(2):137-41. Multidisciplinary team meetings (MDTM) in detection of Alzheimer's disease: data from the IDEM study. Rolland Y1, Tavassoli N, Gillette-Guyonnet S, Perrin A, Hermabessière S, Ousset PJ, Nourhashemi F, Cestac P, Vellas B; IDEM investigators. J Nutr Health Aging. 2013 Feb;17(2):137-4

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

New approach to take care of AD patient in NH

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

60

Q4a. Study criteria: what is the age range of participants at recruitment? To:

until death

Q4b. Study criteria: what are the inclusion criteria?

Male or female, 60 years or over, Institutionalized since 30 days or more, Life expectancy > 1 year, Residents and their GP having received information about the study, Residents and their

GP having expressed their agreement to participate in the study

Q4c. Study criteria: what are the exclusion criteria?

Diagnosed and documented dementia [identified as follows: Identified by the French Healthcare system as suffering from dementia (ALD 15), Benefiting from a specific care program or a specialized follow-up for dementia, Appropriate investigation for dementia diagnosis in medical records, Taking specific drugs for dementia (Cholinesterase inhibitors and/or Memantine)]; GIR = 1; Suffering from a disease jeopardize participation in the study

Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

1,001-5,000

Q5b. What is the expected number of control participants?

501-1,000

Q6a. Please describe what measures are used to characterise participants

AGGIR, number of hospitalizations in two groups, MMSE in cases

Q6b. Are there additional measures for participants with the clinical disorder?

Clock-drawing test, Mini-Cog, five word test, Test of categorical verbal fluency, CAM, one leg balance test, NPI, Mini-GDS, QOL-AD, IADL

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

Yes

If YES please specify

primary end point: Hospitalization in emergency units

Q7. What is the study design?

Prospective cohort

Q8. Are your cases matched by

No match in this study

Q9a. Does your study includes a specialised subset of control participants?

No

Q9b. If your study includes a specialised subset of control participants please describe
Q10a. Is data collection for this study

Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Q11. Are data collected

Only through the study|Through links to medical records

Q12. Is there a system in place to enable re-contact with patients for future studies?

Q13a. Please give information on data stored in a database (1)

Data summarised in database

% Available

70

Q13a. Please give information on data stored in a database (2)

No

% Available

Q13a. Please give information on data stored in a database (3)

Database on spreadsheet (e.g. excel)

% Available

30

Q13a. Please give information on data stored in a database (4)

No

% Available

Q13a. Please give information on data stored in a database (5)

No

% Available

Please specify language used

% Available

70

Q13b. Please give information on how data is held as individual records

No

% Available

Q14a. Are data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource

Q15. What data sharing policy is specified as a condition of use?

Q16a. Are tissues/samples/DNA available to other groups?

No

Q16b i) If yes, please describe below

Q16b. ii) In what form are tissues/samples/DNA supplied?

Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Q17. Is information on biological characteristics available to other groups?

No

Types:

Case Control Studies

Member States:

France

Diseases:

Alzheimer's disease & other dementias, Neurodegenerative disease in general

Years:

2016

Database Categories:

N/A

Database Tags:

N/A